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Abstract
Background: Many cancers including head and neck squamous cell carcinoma (HNSCC) are characterized by a
metabolic rewiring with increased glucose uptake and lactate production, termed as aerobic glycolysis. Targeting
aerobic glycolysis presents a promising strategy for cancer therapy. This study investigates the therapeutic potential
of glycolysis blockage by targeting phosphofructokinase-2/fructose-2, 6-bisphosphatase 3 (PFKFB3) in HNSCC.
Methods: 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15) was used as a selective antagonist of PFKFB3.
Glycolytic flux was determined by measuring glucose uptake, lactate production and ATP yield. PFKFB3
expression was examined using HNSCC tissue arrays. Cell proliferation, apoptosis and motility were analysed.
HNSCC xenograft mouse model and metastasis mouse model were established to examine the therapeutic
efficacy of PFK15 in vivo.
Results: HNSCC showed an increased PFKFB3 expression compared with adjacent mucosal tissues (P < 0.01).
Targeting PFKFB3 via PFK15 significantly reduced the glucose uptake, lactate production and ATP generation in
HNSCC cell lines. PFK15 suppressed cell proliferation, halted cell cycle progression and induced cell apoptosis.
The invadopodia of HNSCC cells was markedly reduced after PFK15 treatment, thereby impairing cell motility
and extracellular matrix degradation ability. The in vivo data from the xenograft mice models proved that
PFK15 administration suppressed the tumor growth. And the results from the metastatic mice models showed
administration of PFK15 alleviated the lung metastasis of HNSCC and extended the life expectancy of mice.
Conclusions: The pharmacological inhibition of PFKFB3 via PFK15 suppressed tumor growth and alleviated
metastasis in HNSCC, offering a promising strategy for cancer therapy.
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Background
Aberrant glucose metabolism is the most common bio-
chemical characteristic of cancer cells [1]. Compared
with normal (quiescent) cells, cancer cells exhibit aerobic
glycolysis or the ‘Warburg effect’, which is characterised by
an increased glucose uptake and lactate production
through a glycolytic pathway even in the presence of
sufficient oxygen [2]. Although the efficacy of ATP gen-
eration by glycolysis is low, the intermediates produced
by glycolysis which shunt into biosynthetic pathways
support the rapid proliferation and survival of cancer cells,
thereby promoting tumor occurrence and progression.
The conversion of fructose-6-phospate to fructose 1, 6-
bisphosphate is the primary rate-limiting and irreversible
reaction amongst a series of reactions in glycolysis; this re-
action is catalysed by phosphofructokinase-1 (PFK1),
which serves as the prominent pacemaker during the
process. Fructose 2, 6-bisphosphate (F26BP) can over-
ride the inhibition by ATP and increased glucose uptake
by interacting with PFK1. Phosphofructokinase-2/
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fructose-2, 6-bisphosphatase 3 (PFKFB3) bears an
oncogene-like regulatory element and benefits the syn-
thesis of F26BP to promote glycolytic flux with its high
kinase activity [3, 4]. Given that this gene is commonly
overexpressed in human cancers, including breast,
colon, ovarian and thyroid carcinomas [5], but is insuf-
ficiently expressed in normal tissues, targeting PFKFB3
presents a promising strategy for cancer treatment. The
overexpression of PFKFB3 is fundamental to the tar-
geted therapy of various cancer types [4]. However,
whether PFKFB3 is overexpressed in head and neck
squamous cell carcinoma (HNSCC) tissues remains
unknown.
As the sixth most common malignancy of the leading
neoplasms around the world [6], HNSCC affects six mil-
lion new patients each year and accounts for over 90%
of head and neck cancers [7, 8]. Most clinical HNSCC
patients suffer from long-term poor prognoses and con-
ditions that have not been improved substantially over
the last three decades partially because of high local re-
currence and frequent distant metastasis [7, 9]. Neo-
plastic invasion and metastasis require a strong
extracellular matrix (ECM) degradation ability [10]
that largely depends on the formation of a specialised
subcellular structure, invadopodia in cancer cells [11].
De Bock et al. found that PFKFB3 affected directional
migration and controlled the formation of lamelli-
podia/filopodia in endothelial cells by mechanistically
compartmentalising with F-actin in these motile pro-
trusions [12]. In addition, many studies revealed the
significance of these F-actin-rich membrane protru-
sions during tumor metastasis [13, 14]. And a recent
study indicated that glycolysis in tumor cells contrib-
uted to the assembly and stability of invadopodia in
tumor cells [15]. Therefore, PFKFB3 may also control
the protrusions in cancer cells, and inhibiting this gene
presents a promising strategy for alleviating the aggres-
sive behaviour of cancer cells.
PFKFB3 suppression can induce the apoptosis of can-
cer cells and halt cell cycles [16]. Moreover, the selective
antagonist of PFKFB3 slows down the growth of trans-
planted tumor in several animal models [16–18]. How-
ever, the therapeutic effects of PFKFB3 suppression
targeting cancer metastasis remain unknown. In this
study, we investigated the effects of targeting PFKFB3
on the growth, apoptosis, migration and invasion of
HNSCC cells, and further explored the possible roles of
this gene in the assembly of functional invadopodia in
HNSCC cell lines. We also tested the therapeutic effi-
cacy of PFK15 by establishing HNSCC xenograft and
metastasis nude mice models, and found that targeting
PFKFB3 offered a promising therapeutic strategy not
only for suppressing primary tumor growth but also for
alleviating distant metastasis in HNSCC.
Methods
Chemicals and antibodies
Dulbecco’s modified Eagle’s medium (DMEM), DMEM/
F12, fetal bovine serum (FBS), penicillin and streptomycin
were obtained from GIBCO (Carlsbad, CA). 1-(4-pyridi-
nyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15; Selleck,
Houston, TX), dimethylsulfoxide (DMSO; Sigma-Aldrich,
St Louis, MO), Gelatin, propidium iodide (PI) and Ribo-
nuclease A (Sigma-Aldrich, St Louis, MO), Mounting
Medium with DAPI (Zhongshan, Beijing, China) were
purchased. MatrigelTM matrix (BD Biosciences, San Jose,
CA), transwell Boyden chamber system and 6-well Ultra-
low Adherence plates (Corning life Sciences, Wilkes Barre,
PA), 0.5% Triton X-100 (MP Biomedical, Solon, OH) were
also used. Epithelial growth factor (EGF) and basic fibro-
blast growth factor (bFGF) were purchased from Pepro-
tech (Rocky Hill, NJ). Antibodies including PFKFB3,
phosphor-Rb, cyclinD1, cleaved-caspase3 (Cell Signaling,
Danvers, MA), Bcl2 (Abcam, Cambridge, UK) and β-
Actin (Santa Cruz, CA) were purchased. All other chemi-
cals were classified as analytical grade reagents.
Cell culture
HNSCC cell lines Cal27 and FaDu were purchased from
the China Center for Type Culture Collection (CCTCC,
Wuhan, China) and cultured according to the manufac-
turer’s instructions with high glucose DMEM containing
10% FBS, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin in a humidified atmosphere of 95% air and 5%
CO2 at 37 °C. Cell viability was measured by the Vi-
CELL cell viability analyzer (Beckman Coulter, Fullerton,
CA).
Human HNSCC tissues array and immunohistochemistry
One hundred eleven pathologically confirmed HNSCC
specimens (including 33 lymph node metastatic samples)
and 57 precancerous normal tissues were collected at the
Hospital of Stomatology, Wuhan University. Then the
fixed tissues were made into a HNSCC tissue arrays with
the assistance of Kindstar Gobal Co. Ltd (Wuhan, China).
The immunohistochemical experiment was performed ac-
cording to our previous procedures [19]. All the proce-
dures were performed in accordance with the guidelines of
National Institutes of Health regarding the use of human
tissues. Briefly, the sections were dewaxed in xylene, rehy-
drated in a graded series of ethanol and double-distilled
water, and antigen retrieved by microwave. After incuba-
tion with 3% hydrogen superoxide and 10% normal goat
serum for 15 min, the sections were then incubated over-
night at 4 °C with monoclonal rabbit anti-human PFKFB3
(Abcam, Cambridge, UK, 1:1000). The antibody binding
was detected by horseradish peroxidase-conjugated sec-
ondary antibody with a diaminobenzene substrate kit
(Dako, Carpinteria, CA) according to the manufacturer’s
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protocol. The negative control slides were obtained by
using PBS instead of the primary antibody. All slices were
scanned by an Aperio ScanScope CS scanner (Epistem,
Cambridge, MA) and quantified using Aperio Quantifica-
tion software (Version 9.1, Epistem) for staining quantifi-
cation as we previously reported [20]. Four random areas
were selected for scanning and quantification. Histoscore
of membrane and nuclear staining was calculated as a per-
centage of different positive cells using the formula (3+) ×
3 + (2+) × 2 + (1+) × 1. Histoscore of pixel quantification
was calculated as total intensity/total cell number. The
threshold for scanning of different positive cells was set ac-
cording to the standard controls provided by Aperio.
Measurement of F26BP, glucose uptake, L-Lactate and ATP
The intracellular level of F26BP, glucose uptake, L-lactate
and ATP output were detected according to manufac-
turers’ instructions. Details were shown in Additional
file 1: Methods.
Determination of viability, tumor spheres formation, cell
cycle progression, apoptosis and apoptosis ability
Detailed procedures were shown in Additional file 1:
Methods.
Cell migration and invasion detection
Cell migration and invasion ability was detected by wound
healing assay and transwell chamber assay, shown in
Additional file 1: Methods.
EdU (5’-ethynl-2’-deoxyuridine) staining assay
The effects of PFK15 on cell proliferation were assessed
by the Cell-Light™ EdU Apollo®488 In Vitro Imaging Kit
according to the manufacturer’s instructions. The num-
ber and proportion of the cells incorporated EdU was
visualized and the fluorescence intensity was quantified
using Image J1.42.
Western blotting
Western blotting analysis was performed according to
our previous procedures [21]. Briefly, Cal27 cells treated
with indicated concentrations of PFK15 for 24 h were
collected, precipitated and lysed. The concentration of
protein was detected by BCA assays. 20 μg of protein
with loading buffer were loaded on 10% SDS-PAGE gels
and transferred PVDF membranes. The membranes
were blocked with 5% nonfat dry milk for 1 h at room
temperature and then probed with primary antibody
overnight at 4 °C at dilutions recommended by the sup-
pliers, including pRb (1:1000), cyclinD1 (1:500), cleaved-
capase-3 (1:1000), Bcl2 (1:2000) and β-Actin (1:20000).
The membranes were incubated with secondary anti-
body conjugated to horseradish peroxidase (HRP) for
1 h at room temperature. Then the membranes were in-
cubated using Pico West chemiluminescent reagent.
Invadopodia analysis and cell immunofluorescence
staining
0.1% Gelatin was labeled by the fluorescent dye Alex 568
using Protein Labeling Kit according to the prescribed
protocol. The cells after different treatment were fixed
with 4% formaldehyde and permeabilized with 0.5% Tri-
ton X-100 in PBS. The cells were then blocked with 5%
BSA for 1 h at room temperature and incubated with
appropriate primary antibodies, PFKFB3 (1:50) and cor-
tactin (1:100) overnight at 4 °C, followed by secondary
antibodies conjugated with Dylight 649 and 408 for 1 h.
The nuclei were stained with mounting medium with
DAPI. After immunofluorescence staining, overhead and
section images were captured by an objective confocal
laser-scanning microscope. The number and area of
invadopodia formed by the cells was determined and
quantified using ImageJ1.42.
Establishment and PFK15 treatment of Cal27 xenograft
model
All animal studies of nude mice were approved and su-
pervised by Animal Care and Use Committee of Wuhan
University. Female athymic nude mice (18–20 g; 6-
8weeks of age) were obtained from the Hunan SJA La-
boratory Animal Co. Ltd (Changsha, Hunan, China). All
the animal experiments have approved from the review
board of the ethics committee of Hospital of Stomatol-
ogy, Wuhan University, and supervised by the Animal
Care and Use Committee of Wuhan University. For xe-
nografts, approximately 1 × 107 viable Cal27 cells were
resuspended in 100 μl PBS solution and subcutaneously
injected into 18 mice. After 2 weeks, the mice were di-
vided into three groups randomly, which received intra-
peritoneal injection of PFK15 (10 mg/kg; n = 6), PFK15
(20 mg/kg; n = 6) or normal saline (vehicle, 100 μl; n =
6) three times per week for 2 weeks. The mice were
monitored every other day for tumor volume by caliper
measurements (Length ×Width2)/2. The mice were eu-
thanized and sacrificed at the indicated time points and
the tumors were harvested for successive histology and
molecular analysis according to standard procedures.
For metastatic models, 10 mice were injected with
Cal27 cells (2 × 106 cells resuspended in 100 μl PBS)
via the tail vein. Two weeks after injection, mice were
randomly divided into two groups and received intra-
peritoneal injection of normal saline (vehicle, 100 μl; n
= 5), PFK15 (10 mg/kg; n = 5) three times per week for
2 weeks, then left for a long period for determining the
survival rate. After 50 days of the first PFK administra-
tion, the mice were euthanized and the lung tumor
nodules were counted after execution. Microscopic
Li et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:7 Page 3 of 12
analysis of metastases was performed on the sections of
formalin-fixed, paraffin-embedded lung tissues stained
with hematoxylin and eosin (H & E) and pan-CK.
Statistical analysis
All experiments were performed at least in triplicate and
each experiment was repeated for three times. Data are
presented as mean ± standard error of mean (SEM).
Graphpad Prism Software (Graphpad Software, Inc) was
used for accomplishing graphs. For statistical analysis
between different treatment groups, a non-parametric
two-sided t-test, and one-way ANOVA were used. Also
a two-way ANOVA was used for group analysis. The
differences were considered statistically significant if
the P-value < 0.05.
Results
Abundant expression of PFKFB3 in HNSCC tissues
Therefore, we explored the expression of PFKFB3 in
HNSCC using tissue arrays (n = 111), in which the normal
adjacent tissues were used as control (n = 57, denoted as
normal mucosa). As shown in Fig. 1, a dramatically en-
hanced immunohistochemical staining was found in most
HNSCC tissues, and staining was almost negative in the
normal mucosa tissues except in some basal layer cells.
Most of the PFKFB3 positive staining was observed in the
nuclei of the carcinoma cells, and cytoplasmic positive sig-
nals were detected in a much weaker level. Some stoma
cells in cancer tissues were also PFKFB3 positive. By ana-
lysing the histoscores of PFKFB3 in both tumor and nor-
mal tissues, we observed a significantly higher expression
of PFKFB3 in HNSCC tissues (Fig. 1b). We also analysed
the PFKFB3 histoscores of the lymph node metastatic and
non-metastatic samples (Fig. 1c). Although those tumors
with positive metastasis had higher PFKFB3 histoscores
than those with negative metastasis, no significant differ-
ence was observed between these samples. Therefore,
PFKFB3 contributes to the development of HNSCC and
may have a role in metastasis.
PFK15 suppresses the glycolytic activity of HNSCC cells
As a potent inhibitor of PFKFB3, PFK15 demonstrates
approximately 100-fold more activities against PFKFB3
than 3-3 (3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one
(3PO) (Fig. 2a) [16]. Using MTT assays, we analysed the
effects of PFK15 on the growth of HNSCC cells, including
Cal27 and FaDu cell lines. As shown in Fig. 2b, PFK15
treatment inhibited the cell growth of Cal27 in a concen-
tration- and time-dependent manner. Similar results were
obtained from the assays on FaDu cells (Additional file 1:
Figure S1a). Given the critical role of PFKFB3 in glycolysis
in most cancer cells by moderating the intercellular level
of F26BP, we then verified the steady-state concentration
of F26BP in HNSCC cells. As shown in Fig. 2c, the intra-
cellular concentration of F26BP was dependently reduced
in Cal27 cells. The intracellular lactate production, glucose
uptake and intracellular ATP generation were then exam-
ined to measure the glycolytic activity of Cal27 cells after
PFK15 treatment. As shown in Fig. 1d-e, the intracellular
lactate production, glucose uptake and intracellular ATP
generation in Cal27 cells were gradually decreased after
PFK15 treatment. PFK15 also showed potent suppressive
effects on the glycolytic activity of FaDu cells, represented
as decreased lactate production, glucose uptake and ATP
generation (Additional file 1: Figure S1b–d). Taken to-
gether, our data showed that PFK15 dramatically sup-
pressed the glycolytic activity of HNSCC cells by
impeding the production of F26BP.
Fig. 1 Abundant expression of PFKFB3 in human HNSCC. a Abundant expression of PFKFB3 in human HNSCC as compared with normal mucosa.
b Histoscore of PFKFB3 in human HNSCC and normal mucosa. c Histoscore of PFKFB3 in the lymph node metastatic and non-metastatic HNSCC
samples. Mean ± S.E.M.; ***P < 0.001
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PFK15 suppresses cell proliferation, halts cell cycle and
induces apoptosis in HNSCC cells
A high rate of glycolysis is required to support neoplastic
growth not only by generating ATP but also by providing
glycolytic intermediates for the synthesis of the necessary
macromolecules for cancer cell mass duplication during
division and proliferation [22]. Therefore, we examined
the potential role of PFK15 in cell proliferation using col-
ony formation and EdU incorporation assays. As shown in
Fig. 3a, PFK15 significantly impaired the clone formation
capability of Cal27 cells even at a relatively low concentra-
tion. At 2.5 μM and 5 μM concentrations, PFK15 almost
entirely inhibited the clone formation of Cal27 cells. The
EdU incorporation assays revealed the potent suppressive
ability of PFK15 on cell proliferation presented as de-
creased EdU positive stained cells (Fig. 3b and c). The
quantitative data suggested that even at 1.25 μM, PFK15
already suppressed more than 50% proliferative potentials
of Cal27 cells. Similar results were obtained using FaDu
cells (Additional file 1: Figure S2a and b). It was reported
PFKFB3 could influence cell cycle transitions and deter-
mine cell fate in several previous studies [17, 23, 24]. We
here also explored the effects of PFKFB3 suppression on
the cell cycle progression and tumor spheres formation,
which was usually used to determine the stemness of can-
cer cells. As shown in Fig. 3d and e, the cell population in
the G1 phase was decreased gradually in a PFK15 dose-
dependent manner. And the cancer cells were halted in
the G2/M phase, which was consistent with previous stud-
ies [24, 25]. Moreover, the similar cell cycle halt was also
determined using FaDu cell line (Additional file 1: Figure
S2c and d). A pervious study demonstrated the higher
expression of PFKFB3 in cancer stem cells (CSCs) rather
than the induced pluripotent stem cells (iPS), which might
be able to be used to distinguish these two kind of stem
cells [23]. Thus, tumor sphere formation assays were car-
ried out to explore whether the stemness of HNSCC cells
was changed after PFK15 treatment. Our results demon-
strated that the number and the size of the tumor spheres
formed by Cal27 single cells were dramatically decreased
in the presence of PFK15 (Fig. 3f). And the results were
also determined using FaDu cells (Additional file 1: Figure
S2e). These results indicated the important role of
PFKFB3 in the maintenance of cancer stem cells. We
further explored whether PFK15 induced apoptosis in
HNSCC cells. Annexin V-FITC/PI double staining was
then performed to analyse the apoptosis of Cal27 cells
after PFK15 treatment. The apoptotic cell population was
quantitatively assessed via flow cytometric analysis
(Fig. 3g). Although more apoptotic cells were detected in
PFK15 treated group than in control group, PFK15
showed a weaker efficacy in inducing cell apoptosis than
in suppressing cell proliferation. TUNEL Apo-Green de-
tection assays were used to investigate apoptotic cell death
by identifying fragmented DNA in Cal27 cells with the
condensed green fluorescence in cell nuclei. As shown in
Fig. 3h, the TUNEL positive staining of Cal27 cells in-
creased after treatment with various PFK15 concentrations
for 24 h. The expression levels of cell-proliferation- and
apoptosis-related genes were examined by western blots
(Fig. 3i). PFK15 significantly reduced the expressions of
pRb, cyclin D1 and Bcl2, and upregulated the expression
of cleaved caspase3 (CL-caspase3). In sum, targeting
PFKFB3 by its selective suppressant PFK15 significantly
suppressed cell proliferation and induced cell apoptosis in
HNSCC.
Fig. 2 PFK15 suppresses the glycolytic activity of HNSCC cells. a Molecular structure of 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15).
b Cell growth determined by MTT assays in Cal27 cells after PFK15 treatment. c Measurement of fructose 2,6-bisphosphate (F26BP) in Cal27 cells
after PFK15 treatment. d Glucose uptake was analyzed in Cal27 cells using 2-NBDG. e Lactate productionof Cal27 cells treated with PFK15 were
detected. f ATP generation inside of the Cal27 cells treated with PFK15 were measured. Mean ± S.E.M.; *P < 0.05, **P < 0.01, ***P < 0.001
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PFK15 inhibits cell migration and invasion of HNSCC cells
To identify the potential roles of PKF15 in HNSCC local
invasion and metastasis, the effects of PFK15 on cell mi-
gration and invasion were measured using wound heal-
ing assays and a transwell chamber system. As shown in
Fig. 4a and b, PFK15 significantly reduced the migratory
ability of Cal27 cells at 1.25 μM and 2.5 μM after 12 h
treatment, at which concentrations PFK15 halted cell
proliferation without causing significant cell death. The
results from the transwell chamber system also showed
that PFK15 suppressed the migration of Cal27 cells. We
explored the invasive capability of Cal27 after PFK15
treatment by adding Matrigel on the upper chamber of
the transwell system. As expected, PFK15 remarkably re-
duced the number of cells that crossed the Matrigel-
coated semipermeable membrane (Fig. 4c and d). The
Fig. 3 PFK15 suppresses cell proliferation, halts cell cycle and induces cell apoptosis in HNSCC cells. a PFK15 suppressed the colony formation
of Cal27 cells in 2 weeks. b EdU incorporation assays indicated PFK15 inhibited the cell proliferation of Cal27 cells. c The quantitative data of the
EdU incorporation assays. d PI staining revealed that PFK15 halted cell cycle progression and induced G2 phase arrest. e The quantitative data of
cell cycle analysis based on Dean-Jett-Fox model. f Tumor sphere formation assays indicated PFK15 decreased the cancer stem cell population in
Cal27 cells. g Annexin V-FITC/PI double staining demonstrated PFK15 induced moderate cell apoptosis of Cal27 cells. h TUNEL assays indicated
PFK15 induced apoptotic cell death of Cal27 cells. i Protein expressions of phosphor-Rb (pRb), cyclin D1, Bcl2 and cleaved caspase3 (CL-caspase3)
in PFK15 treated Cal27 cells were measured by western blots. Mean ± S.E.M.; **P < 0.01, ***P < 0.001
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quantitative data confirmed the abovementioned results.
The suppressive effects of PFK15 on cell migration and
invasion were also observed on FaDu cells (Additional
file 1: Figure S3). In sum, using PFK15 to inhibit glycoly-
sis in HNSCC cells could also dramatically suppress cell
migration and invasion, suggesting that blockage of
PFKFB3 was a promising prospect against tumor metas-
tasis in HNSCC.
PFK15 significantly impairs the invadopodia formation of
HNSCC cells
After proving that the blockage of glycolysis by PFK15
could suppress cell migration and invasion in HNSCC,
we investigated whether targeting PFKFB3 impaired the
function of invadopodia in HNSCC cells. The invadopo-
dia formation of Cal27 cells was analysed by plating cells
on the coverslips coated with Alexa568-labeled gelatine
matrix, and the black holes that reflected ECM degrad-
ation were observed under a confocal laser scanning
microscope. After using the quantification mask by
virtue of Image J software, we found that the number
and area of dark spots in Alexa568-labelled gelatin were
significantly reduced after PFK15 treatment, which sug-
gested a significant reduction in the ECM degradation
ability of Cal27 cells (Fig. 5a). Such reduced ECM deg-
radation ability reflected the impaired invadopodia func-
tion. Through the immunofluorescent staining of F-actin
and cortactin—the core components of invadopodia, we
further analysed the assembly of this F-actin-rich mem-
brane protrusion. As shown in Fig. 5b, the co-location of
F-actin and cortactin in Cal27 cells as well as the black
holes in the Alexa568-labeled gelatine matrix indicated
the formation of the invadopodia in Cal27 cells with
ECM degradation capability. The obviously decreased
number of dots in PFK15-treated Cal27 cells suggested
the remarkably suppressed formation of invadopodia.
The quantitative analysis results indicated that PFK15
reduced the ECM degradation ability of Cal27 cells by
more than half at 2.5 μM and almost completely sup-
pressed the ECM degradation of Cal27 cells at 5 μM
(Fig. 5c). The quantitative data of invadopodia positive/
total cells confirmed that PFK15 treatment significantly
decreased the invadopodia of Cal27 cells (Fig. 5d).
A recent study demonstrated that PFKFB3 could regu-
late the protrusions of endothelial cells by binding to actin
and generating ATPs for assembling protrusions. There-
fore, we tested the subcellular localisation of PFKFB3 in
Cal27 cells. The fluorescent images clearly showed that al-
though most of PFKFB3 was localised in the nuclei of the
tumor cells, the positive staining of PFKFB3 could also be
detected in the invadopodia (Fig. 5e). Our supplementary
data suggested that PFK15 treatment also impaired the la-
mellipodia of Cal27 cells (Additional file 1: Figure S4a and
b). The positive staining of PFKFB3 was also detected in
Fig. 4 PFK15 reduces the migratory and invasive abilities of Cal27 cells. a The effects of PFK15 on the migration of Cal27 cells were tested by
wound healing assays. b The quantitative data of the wound healing assays. c The migration and invasion of Cal27 cells that were treated
with PFK15 were analyzed by transwell system. d The quantitative data of the migration and invasion assays using transwell chamber system.
Mean ± S.E.M.; **P < 0.01, ***P < 0.001
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the lamellipodia clearly. By contrast, the visualisation of
mitochondria using COX IV revealed that all the mito-
chondria were localised around the nuclei of Cal27 cells
and excluded from lamellipodia (Additional file 1: Figure
S4c). The ATPs generated through oxidative phosphoryl-
ation (OXPHOS) might not infiltrate into the formation
of these protrusions. In sum, PFK15 evidently impairs the
migration and invasion of tumor cells by decreasing the
functional invadopodia and lamellipodia formation.
PFK15 inhibits tumor growth in a HNSCC xenograft
mouse model
To verify the therapeutic potentials of PFK15 in HNSCC
treatment, a HNSCC xenograft model was established
by subcutaneously injecting Cal27 cells into the flanks of
the nude mice according to our previous study [20].
After 14 days of the injection of tumor cells, the mice
received treatment, and the tumor volume and mice
weights were measured every other day. Figure 6a
showed the tumor cells implantation and drug adminis-
tration strategies. The tumor growth curve revealed that
PFK15 significantly slowed the development of the tu-
mors at a 10 mg/kg concentration, but gradually reduced
the tumor volume and almost completely abolished the
tumor development at a 20 mg/kg concentration (Fig. 6b).
After a 3-week PFK15 treatment, the mice were eutha-
nized and the tumors were harvested. Figure 6c showed
the tumors excised from each treatment group. The
Fig. 5 PFK15 impairs the formation and function of invadopodia in Cal27 cells. a The extracellular matrix (ECM) degradation ability of Cal27 cells after
PFK15 treatment were measured by seeding tumor cells on the Alexa568-gelatin coated coverslips. b PFK15 impairs the formation of invadopodia
inCal27 cells, which were detected by co-localisation of cortactin, F-actin and the black holes on the Alexa568-gelatin coated coverslips. c The
quantitative data of the degraded matrix on the Alexa568-gelatin coated coverslips. d The quantitative data of the invadopodia formation per
Cal27 cells. e The localisation of PFKFB3 in the invadopodia of Cal27 cells. Mean ± S.E.M.; ***P < 0.001
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tumor weights shown in Fig. 6d further confirmed the ex-
cellent antitumor effects of PFK15, especially at a 20 mg/
kg concentration. The body weights of mice after PFK15
treatment were comparable to those of the mice treated
with PBS (control group), thereby suggesting the limited
systemic toxicity of PFK15 during the treatment (Fig. 6e).
The specimens from the xenografts were stained with
PFKFB3, Ki67 and TUNEL. The immunohistochemistry
results revealed that PFK15 did not affect the expression
level of PFKFB3, but remarkably reduced the expression
of Ki67 whilst inducing cell apoptosis in vivo (Fig. 6f).
Therefore, targeting PFKFB3 by virtue of its selective sup-
pressant PFK15 significantly impeded the development of
HNSCC and even abolished the progression of HNSCC in
a xenograft mouse model.
PFK15 reduces the metastatic potential of HNSCC cells in
vivo
To determine the potential therapeutic effects of PFK15
in tumor metastasis, a HNSCC metastatic mice model
was established by injecting Cal27 cells into female
BALB/c nude mice via tail vein. Two weeks after injec-
tion of tumor cells, 10 mg/kg PKF15 was administrated
via intraperitoneal injection (every other day, 3 days/
week for 2 weeks). Fifty days after the first PFK
administration, the mice were euthanized and their lungs
were harvested. The representative photos of the lungs
harvested from the mice suggested that the metastasis
nodules were dramatically decreased in mice with
PFK15 treatment compared with those of the mice in
the control group (Fig. 7a). Microscopic metastases to
the lung were confirmed via H & E staining and pan-CK
immunohistochemistical staining. As shown in Fig. 7b,
the compact cell aggregations, which were further evi-
denced as tumor cells because of their positive staining
of human pan-CK, were frequently observed in the lungs
of the mice without any treatment, and the cell aggrega-
tions were much less and smaller in the lungs of the
mice treated with PFK15. The lungs of each mouse from
the control group had approximately 6 to 15 micrometa-
static foci. By contrast, less than three micrometastatic
foci were found in the lungs of three mice treated with
PFK15, while the lungs of the other mice were free from
metastasis. The incidence of metastasis was measured by
the number of pulmonary metastatic clones (Fig. 7c),
which confirmed the reduced metastatic ability of Cal27
cells in the model after PFK15 treatment. The survival
curves demonstrated that PFK15 treatment extended the
life expectancy of the mice suffering from the metastasis
of Cal27 cells (Fig. 7d). In sum, the administration of
Fig. 6 PFK15 inhibits the tumor growth in a HNSCC xenograft mice model. a The nude mice bearing xenograft were treated with 10 mg/kg and
20 mg/kg PFK15 intraperitoneally (i.p) every other day for 2 weeks. b Tumor growth was measured every other day. c Photos of the xenograft
harvested from the nude mice after treatment with PFK15. d The tumor weights were measured after harvest from the carcinoma-bearing
mice. e The mice weights were measured to examine the systematic toxicity of PFK15. f The expression of PFKFB3 and Ki67 were detected by
immunohistochemistry, and the apoptotic cell death were examined by TUNEL assays. Mean ± S.E.M.; *P < 0.05, **P < 0.01, ***P < 0.001
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PFK15 significantly prevents the distant metastases
formation of HNSCC cells, thereby extending the life ex-
pectancy of these mice. This finding is consistent with
the migration and invasion suppressive effects in the in
vitro assays.
Discussion
The metabolic switch from OXPHOS to aerobic glycoly-
sis in cancer cells has been defined by Hanahan and
Weinberg in 2011 as an emerging hallmark of cancer
[26]. Despite its low ATP-generation efficacy, the in-
creased glycolysis accompanied with a markedly in-
creased uptake and utilisation of glucose in cancer cells
could provide sufficient energy for cell survival and
allowed for the diversion of glycolytic intermediates
into various biosynthetic pathways, thereby facilitating
the biosynthesis of the macromolecules and organelles
required for assembling new cells. Many studies reveal
that the execution of aggressive tumor agenda required
a specific rewiring of the metabolic flux. The relation-
ship between the glycolysis and metastasis in cancers
has been increasingly acknowledged [27]. By targeting
one of the most important glycolytic rate-limiting en-
zymes, PFKFB3, using its selective inhibitor PFK15, we
proved that the blockage of glycolysis in HNSCC cells
not only halted tumor growth by inhibiting cell prolif-
eration but also alleviated cancer metastasis by sup-
pressing the formation of protrusions. By establishing
xenograft mice models and metastatic mice models, the
aforementioned conclusions were further supported in
vivo, validating the targeting of PFKFB3 as a promising
strategy for HNSCC treatment.
Although the relationship between glycolysis and me-
tastasis during cancer progression remains unknown,
glycolysis is generally believed to be involved in several
steps of metastasis. The extracellular acidosis (low pHe),
which was associated with an elevated glycolytic flux
due to the production and exportation of lactate through
glycolysis, was considered a crucial factor for the detach-
ment of tumor cells from neighbouring cells or ECM
[28]. Extracellular acidosis also stimulated the secretion
and/or activation of several hydrolases, including cathep-
sin and matrix metalloproteinases, which degraded the
ECM components. The increased lactate in a micro-
environment taken up by endothelial cells stimulated the
secretion of interleukin (IL)-8 by activating the NF-κB
pathway and promoting the formation of novel blood
vessels that provide routes for cancer metastasis to dis-
tant organs. The accelerated glycolytic flux shunted the
intermediates into the pentose phosphate pathway
(PPP), which not only supported tumor cell proliferation
but also facilitated tumor metastasis by preventing
tumor cells from detachment-induced apoptosis (anoi-
kis) during circulation [27, 29]. A recent study showed
that PPP enhanced the tyrosine phosphorylation/activa-
tion of the HGF receptor, c-MET, which promoted cell
migration and invasion by activating downstream path-
ways [30]. Glycolysis is also indispensable in the
Fig. 7 PFK15 prevents HNSCC distant metastasis in a HNSCC metastasis nude mice model. a Representative photos of the lung harvested from
the mice bearing HNSCC metastasis treated with or without PFK15. b The metastatic nodules in the lung were determined by hematoxylin
eosin (H & E) staining and human pan-CK immunohistochemical staining. c The quantitative of data of lung metastasis by counting the
micrometastatic nodules per mice. d Kaplan-Meier survival curve of the mice treated with or without PFK15 were depicted.
Mean ± S.E.M.; ***P < 0.001
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production of high amounts of ATP in these protru-
sions, which ensure a sufficient energy demand for dy-
namic cytoskeleton remodeling during cell migration
and invasion. Another study revealed that the blockage
of glycolysis, instead of mitochondrial OXPHOS, im-
paired the formation and function of invadopodia in sev-
eral cancer cells [15]. Several glycolytic enzymes,
including glyceraldehyde 3-phosphate dehydrogenase
(G3PDH), pyruvate kinase M2 (PKM2) and lLactate de-
hydrogenase A (LDH-A), were also found in the specia-
lised protrusions, including lamellipodia and
invadopodia [15].
Here, we observed that the blockage of glycolysis by
targeting PFKFB3 could suppress the migration and in-
vasion of HNSCC cells, which might be attributed to the
reduced formation of invadopodia and lamellipodia. This
study is the first to reveal the compartmentalisation of
PFKFB3 in invading protrusions in cancer cells, as we
found the co-localisation of PFKFB3 and the aggregation
of F-actin (in both invadopodia and invadopodia) and
ECM degradation spots (in invadopodia). This finding
was consistent with that of a previous study, in which
PFKFB3 was localised in the lamellipodia in endothelial
cells [31]. The distribution of mitochondria only around
the nuclei suggested that glycolysis might be main en-
ergy source for the assembly of invadopodia as proven in
another study [15]. Importantly, we provided strong evi-
dence that targeting PFKFB3 by PFK15 administration
significantly reduced the lung metastases of the HNSCC
cells in a mice model, and extended the life span of the
mice. Therefore, targeting PFKFB3 offers a promising
approach for preventing metastasis, and further inves-
tigations must be conducted to reveal precisely the
molecular details during the formation and functionali-
zation of invadopodia.
The persistence of aerobic glycolysis in many cancers
provides a wide range of potential targets for therapy.
We chose PFKFB3 as our target for several reasons.
Firstly, PFKFB3 was widely expressed in several cancer
types, and we here confirmed the high expression of
PFKFB3 in HNSCC tissues but not in the adjacent
normal tissues. Secondly, compared with the widely used
glucose analogue 2-deoxy-D-glucose (2-DG), which may
cause severe toxic and systemic adverse effects as its
nearly inhibiting glycolytic activity completely [32], the
systemic administration of 3PO, a small molecule antag-
onist of PFKFB3, only results in the partial and transient
reduction of glycolysis without producing severe toxicity
in normal tissues [12]. Developed by Clem et al. as a
3PO derivative in 2013 [16], PFK15 demonstrated ap-
proximately 100-fold more activities against PFKFB3 com-
pared with 3PO. Thirdly, the blockage of PFKFB3 could
inhibit the pathological angiogenesis without affecting the
normal blood vessels [12]. Aberrant angiogenesis not only
contributed to tumor growth by supporting nutrients and
oxygen but was also involved in distant metastasis because
of its high permeability. PFK15 significantly reduced the
formation of novel blood vessels in the HNSCC xenografts
(data not shown), which might contribute to the suppres-
sion of tumor growth and the alleviation of distant metas-
tasis. Apart from mediating glycolysis acceleration,
PFKFB3 might also involve in other tumor progressions.
A previous study reported that PFKFB3 in the nucleus-
generated F26BP could activate cyclin-dependent kinases
and result in the phosphorylation and degradation of the
Cip/Kip protein p27, thereby accelerating cell cycle and
promoting cell proliferation [33]. And of interest, a recent
study showed PFKFB3 controled human tongue tumor
growth by responding to the circadian clock outputs [34].
Conclusions
In sum, our study is the first to report that targeting
PFKFB3 using its selective antagonist PFK15 not only
halts the cell proliferation of HNSCC cells but also im-
pairs their motilities for distant metastasis. The impaired
motility of HNSCC cells might be attributed to the fact
that the blockage of glycolysis in HNSCC impeded the
formation of functional invadopodia and lamellipodia,
which were the specialised protrusions that facilitate
cell migration and invasion. By establishing HNSCC
xenograft mice models and metastatic mice models, we
further tested the therapeutic efficacy of PFK15 on
HNSCC in vivo, and proved that the blockage of gly-
colysis by targeting PFKFB3 not only suppressed tumor
growth but also alleviated the distant metastasis of
HNSCC, reflecting the promising application of PFK15
for HNSCC treatment.
Additional file
Additional file 1: Additional Materials and Methods. Figure S1. PFK15
inhibits the cell growth and glycolytic activity of FaDu cells. Figure S2.
PFK15 suppresses cell proliferation and halts cell cycle in FaDu cells.
Figure S3. PFK15 decreases the migratory and invasive abilities of FaDu
cells. Figure S4. PFK15 impairs the formation lamellipodia in Cal27 cells.
(DOC 910 kb)
Abbreviations




The authors would like to thank the anonymous reviewers for the insightful
suggestions which greatly improved this MS.
Funding
This work is supported by National Natural Science Foundation of China
(81602780) to ZW, (81600385) to RJG. ZW is supported by the supporting
program for young excellent talents by China Association for Science and
Technology. JJ is supported by Seed Foundation of Scientific Research
Innovation by Wuhan University.
Li et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:7 Page 11 of 12
Availability of data and materials
Data sharing is applicable to this article.
Authors’ contributions
ZW designed the project. LHM, YJG, ZW, LJZ and YZL performed the
experiments and analysed the data. ZW and LHM wrote the manuscript.
RJG, CG and JJ revised the manuscript. WWM was responsible for clinical
sampling and logistic of HNSCC specimens and precancerous normal
tissues. ZW and JJ supervised the project. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All subjects signed an informed consent form. The study was approved from
the review board of the ethics committee of Hospital of Stomatology, Wuhan
University. Written informed consent was obtained from all parents for use of
the specimens.
Author details
1The State Key Laboratory Breeding Base of Basic Science of Stomatology
(Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education,
School and Hospital of Stomatology, Wuhan University, Wuhan 430079, China.
2Department of Oral and Maxillofacial Surgery, School and Hospital of
Stomatology, Wuhan University, No237, Luoyu Road, Hongshan District, Wuhan
430079, China. 3Oral Medical Center, Xiangya Hospital, Central South University,
Changsha, Hunan 410000, China.
Received: 7 September 2016 Accepted: 22 December 2016
References
1. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial
oxidative metabolism as an anti-metastasis mechanism. Cancer Lett.
2015;356:156–64.
2. Ashrafian H. Cancer’s sweet tooth: the Janus effect of glucose metabolism
in tumorigenesis. Lancet. 2006;367:618–21.
3. Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han JH,
Metz C, Bucala R. An inducible gene product for 6-phosphofructo-2-kinase
with an AU-rich instability element: role in tumor cell glycolysis and the
Warburg effect. Proc Natl Acad Sci. 1999;96:3047–52.
4. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R,
Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-
2, 6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;
62:5881–7.
5. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by
6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatases in cancer. Exp Mol
Pathol. 2009;86:174–9.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin. 2011;61:69–90.
7. Feng Z, Xu Q, Chen W. Epigenetic and genetic alterations-based molecular
classification of head and neck cancer. Expert Rev Mol Diagn. 2012;12:279–90.
8. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer.
Oral Oncol. 2009;45:309–16.
9. Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR,
Shah JP, Rao PH, Singh B. Identification of novel prognosticators of
outcome in squamous cell carcinoma of the head and neck. J Clin Oncol.
2004;22:3965–72.
10. Chiang SP, Cabrera RM, Segall JE: Tumor Cell Intravasation. A review in the
theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell
Physiol 2016:ajpcell 00238 02015. doi:10.1152/ajpcell.00238.2015.
11. Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC. Dynamic
interactions of cortactin and membrane type 1 matrix metalloproteinase at
invadopodia: defining the stages of invadopodia formation and function.
Cancer Res. 2006;66:3034–43.
12. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B,
Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J. Partial
and transient reduction of glycolysis by PFKFB3 blockade reduces pathological
angiogenesis. Cell Metab. 2014;19:37–48.
13. Ridley AJ. Life at the leading edge. Cell. 2011;145:1012–22.
14. Murphy DA, Courtneidge SA. The ‘ins’ and ‘outs’ of podosomes and
invadopodia: characteristics, formation and function. Nat Rev Mol Cell
Biol. 2011;12:413–26.
15. van Horssen R, Buccione R, Willemse M, Cingir S, Wieringa B, Attanasio F.
Cancer cell metabolism regulates extracellular matrix degradation by
invadopodia. Eur J Cell Biol. 2013;92:113–21.
16. Clem BF, O’Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA, Klarer
AC, Redman R, Miller DM, Trent JO, et al. Targeting 6-phosphofructo-2-
kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther.
2013;12:1461–70.
17. Calvo MN, Bartrons R, Castaño E, Perales JC, Navarro-Sabaté A, Manzano
A. PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay
and inhibits anchorage-independent growth in HeLa cells. FEBS Lett.
2006;580(13):3308–3314.
18. Lea MA, Guzman Y, Desbordes C. Inhibition of growth by combined treatment
with inhibitors of lactate dehydrogenase and either phenformin or inhibitors
of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 3. Anticancer Res.
2016;36:1479–88.
19. Jia J, Bai Y, Fu K, Sun ZJ, Chen XM, Zhao YF. Expression of allograft
inflammatory factor‐1 and CD68 in haemangioma: implication in the
progression of haemangioma. Br J Dermatol. 2008;159:811–9.
20. Zhang L, Zhang W, Wang YF, Liu B, Zhang WF, Zhao YF, Kulkarni AB, Sun ZJ.
Dual induction of apoptotic and autophagic cell death by targeting survivin
in head neck squamous cell carcinoma. Cell Death Dis. 2015;6:e1771.
21. Zhao Y, Chen G, Zhang W, Xu N, Zhu JY, Jia J, Sun ZJ, Wang YN, Zhao YF.
Autophagy regulates hypoxia‐induced osteoclastogenesis through the
HIF‐1α/BNIP3 signaling pathway. J Cell Physiol. 2012;227:639–48.
22. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic
requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.
23. Cieslar-Pobuda A, Jain MV, Kratz G, Rzeszowska-Wolny J, Ghavami S, Wiechec E.
The expression pattern of PFKFB3 enzyme distinguishes between induced-
pluripotent stem cells and cancer stem cells. Oncotarget. 2015;6:29753–70.
24. Colombo SL, Palacios-Callender M, Frakich N, Carcamo S, Kovacs I,
Tudzarova S, Moncada S. Molecular basis for the differential use of
glucose and glutamine in cell proliferation as revealed by synchronized
HeLa cells. Proc Natl Acad Sci U S A. 2011;108:21069–74.
25. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA,
Arumugam S, Dean WL, Eaton J, et al. Small-molecule inhibition of 6-
phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Mol Cancer Ther. 2008;7:110–20.
26. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144:646–74.
27. Payen VL, Porporato PE, Baselet B, Sonveaux P. Metabolic changes associated
with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate
pathway. Cell Mol Life Sci. 2016;73:1333–48.
28. Chen KH, Tung PY, Wu JC, Chen Y, Chen PC, Huang SH, Wang SM. An acidic
extracellular pH induces Src kinase-dependent loss of beta-catenin from the
adherens junction. Cancer Lett. 2008;267:37–48.
29. Kamarajugadda S, Stemboroski L, Cai Q, Simpson NE, Nayak S, Tan M, Lu J.
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol.
2012;32:1893–907.
30. Chan B, Vanderlaan PA, Sukhatme VP. 6-phosphogluconate dehydrogenase
regulates tumor cell migration in vitro by regulating receptor tyrosine
kinase c-Met. Biochem Biophys Res Commun. 2013;439:247–51.
31. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR,
Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G, et al. Role of
PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651–63.
32. Nef HM, Mollmann H, Joseph A, Troidl C, Voss S, Vogt A, Weber M, Hamm CW,
Elsasser A. Effects of 2-deoxy-D-glucose on proliferation of vascular smooth
muscle cells and endothelial cells. J Int Med Res. 2008;36:986–91.
33. Yalcin A, Clem B, Imbert-Fernandez Y, Ozcan S, Peker S, O’Neal J, Klarer A,
Clem A, Telang S, Chesney J. 6-phosphofructo-2-kinase (PFKFB3) promotes
cell cycle progression and suppresses apoptosis via Cdk1-mediated
phosphorylation of p27. Cell Death Dis. 2014;5:e1337.
34. Chen L, Zhao J, Tang Q, Li H, Zhang C, Yu R, Zhao Y, Huo Y, Wu C.
PFKFB3control of cancer growth by responding to circadian clock
outputs. Scientific Reports. 2016;6:24324.
Li et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:7 Page 12 of 12
